These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19460157)

  • 1. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Hueber W; Tomooka BH; Batliwalla F; Li W; Monach PA; Tibshirani RJ; Van Vollenhoven RF; Lampa J; Saito K; Tanaka Y; Genovese MC; Klareskog L; Gregersen PK; Robinson WH
    Arthritis Res Ther; 2009; 11(3):R76. PubMed ID: 19460157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients.
    Zivojinovic S; Pejnovic N; Sefik-Bukilica M; Kovacevic L; Soldatovic I; Bugarski D; Mojsilovic S; Damjanov N
    Inflammopharmacology; 2012 Dec; 20(6):323-30. PubMed ID: 22733231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.
    Kapoor SR; Filer A; Fitzpatrick MA; Fisher BA; Taylor PC; Buckley CD; McInnes IB; Raza K; Young SP
    Arthritis Rheum; 2013 Jun; 65(6):1448-56. PubMed ID: 23460124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
    Fabre S; Dupuy AM; Dossat N; Guisset C; Cohen JD; Cristol JP; Daures JP; Jorgensen C
    Clin Exp Immunol; 2008 Aug; 153(2):188-95. PubMed ID: 18549443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Rheumatol Int; 2010 Feb; 30(4):451-4. PubMed ID: 19506882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
    Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
    Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
    Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.
    Cole P; Rabasseda X
    Drugs Today (Barc); 2004 Apr; 40(4):281-324. PubMed ID: 15190385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
    Potter C; Hyrich KL; Tracey A; Lunt M; Plant D; Symmons DP; Thomson W; Worthington J; Emery P; Morgan AW; Wilson AG; Isaacs J; Barton A;
    Ann Rheum Dis; 2009 Jan; 68(1):69-74. PubMed ID: 18375541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
    Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
    Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.